Koshimichi H - Search Results

1

Open-label study of the safety, pharmacokinetics, and effectiveness of a 2 mg/kg dose of baloxavir marboxil 2% granules in children <20 kg with influenza.

Sonoyama T, Sakaguchi H, Koshimichi H, Noshi T, Tsuchiya K, Uehara T. Sonoyama T, et al. Among authors: koshimichi h. J Infect Chemother. 2021 Aug;27(8):1223-1229. doi: 10.1016/j.jiac.2021.05.009. Epub 2021 May 24. J Infect Chemother. 2021. PMID: 34045119 Free article.

2

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications.

Koshimichi H, Retout S, Cosson V, Duval V, De Buck S, Tsuda Y, Ishibashi T, Wajima T. Koshimichi H, et al. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00119-20. doi: 10.1128/AAC.00119-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32312784 Free PMC article.

3

Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients.

Koshimichi H, Ishibashi T, Wajima T. Koshimichi H, et al. J Pharm Sci. 2019 Sep;108(9):3112-3117. doi: 10.1016/j.xphs.2019.04.010. Epub 2019 Apr 16. J Pharm Sci. 2019. PMID: 30998942

4

Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.

Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T. Koshimichi H, et al. Clin Drug Investig. 2018 Dec;38(12):1189-1196. doi: 10.1007/s40261-018-0710-9. Clin Drug Investig. 2018. PMID: 30288682 Free PMC article. Clinical Trial.

5

Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza.

Koshimichi H, Tsuda Y, Ishibashi T, Wajima T. Koshimichi H, et al. J Pharm Sci. 2019 May;108(5):1896-1904. doi: 10.1016/j.xphs.2018.12.005. Epub 2018 Dec 15. J Pharm Sci. 2019. PMID: 30557562 Free article.

6

Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.

Kawaguchi N, Koshimichi H, Ishibashi T, Wajima T. Kawaguchi N, et al. Among authors: koshimichi h. Clin Drug Investig. 2018 Nov;38(11):1053-1060. doi: 10.1007/s40261-018-0697-2. Clin Drug Investig. 2018. PMID: 30203386 Clinical Trial.

7

Contribution of protein binding, lipid partitioning, and asymmetrical transport to drug transfer into milk in mouse versus human.

Ito N, Ito K, Koshimichi H, Hisaka A, Honma M, Igarashi T, Suzuki H. Ito N, et al. Among authors: koshimichi h. Pharm Res. 2013 Sep;30(9):2410-22. doi: 10.1007/s11095-013-1085-5. Epub 2013 May 31. Pharm Res. 2013. PMID: 23722410

8

Analysis and prediction of drug transfer into human milk taking into consideration secretion and reuptake clearances across the mammary epithelia.

Koshimichi H, Ito K, Hisaka A, Honma M, Suzuki H. Koshimichi H, et al. Drug Metab Dispos. 2011 Dec;39(12):2370-80. doi: 10.1124/dmd.111.040972. Epub 2011 Sep 22. Drug Metab Dispos. 2011. PMID: 21940904

9

Analyzing the worldwide progression of COVID-19 cases and deaths using nonlinear mixed-effects model.

Koshimichi H, Hisaka A. Koshimichi H, et al. PLoS One. 2024 Aug 12;19(8):e0306891. doi: 10.1371/journal.pone.0306891. eCollection 2024. PLoS One. 2024. PMID: 39133667 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters